In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride Drug Master File in Korea ((1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride. The MFDS reviews the (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride KDMF as part of the drug registration process and uses the information provided in the (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride suppliers with KDMF on PharmaCompass.